SOURCE: Easton Pharmaceuticals, Inc.
TORONTO, ON--(Marketwired - May 6, 2014) - Easton Pharmaceuticals Inc. (OTC: EAPH) announces it had provided BMV Medica S.A. de C.V. confirmation of final payment to BMV towards it Mexican initiatives regarding Easton's Viorra product. Announces new Michigan proposal in its medical marijuana initiatives.
As previously disclosed, Easton has engaged and announced that BMV Medica S.A. de C.V. has been appointed as its sole exclusive distributor in Mexico. BMV has signed an agreement with Easton on utilizing its resources and relationships aimed at marketing Viorra successfully in a market that BMV believes can be positioned as a leading-edge daily-use woman's health product to also assist in the treatment of FSAD type conditions. Easton has given BMV its approval to launch certain initiatives once manufacturing has been set up in Mexico, currently being addressed by BMV, which when complete, could also supply the United States, Canadian and International markets.
BMV Medica, S.A. de C.V. was originally set up to be solely a regulatory boutique firm, its principals have been instrumental in the approval in Mexico of products such as pregnancy tests, combination drug/device products, other medicinal products and nutritional supplements. Recently BMV has entered into Sales & Distribution, and now has the following products it offers for sale directly to hospitals, and through sub-distributors: EvaPro pregnancy test; Alvim: Cefotaxime injectable antibiotic, 1 gm presentation; Auroviax: Ceftriaxone, injectable antibiotic in 1 gm presentation; Meronny: Meropenem injectable antibiotic offered as 500 mg and 1 gm presentations; Tandeaur: Tramadol, injectable pain relief, indicated for chronic, moderate to moderately severe pain in a category just below the narcotic analgesics, offered in 50 and 100 mg presentations.
Ms. Mendoza Vazquez, President of BMV stated: "We are adding to our Women's Health product offerings, and believe Viorra will be one of our major assets once launched. With the pregnancy tests, we are constantly faced with stiff competition, and we are excited that Viorra will have some unique characteristics which we hope to leverage into strong sales once launched."
In other developments, on May 2nd, Easton Pharmaceuticals signed a new proposal document to enter into a joint venture with a medical marijuana, revenue generating company in the State of Michigan who are current owners of an operating dispensary. These negotiations are concurrent with others in both the Unites States and Canada. Easton has been requested and advised to not make any additional disclosures regarding this proposal and others for various reasons including regulatory concerns in those jurisdictions. However a much more detailed announcement on all of its medical marijuana initiatives in both the U.S. and Canadian markets is to set to follow that will shed light on its funds allocation.
In other developments, the drafting of its SEC document to raise an additional $5 Million in financing has been completed and is set to be filed with the securities and exchange commission.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter, topical daily use product and aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder).
For More Information Visit:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.